Global Otic Drugs Market – Industry Trends and Forecast to 2029

Análise e dimensão do mercado

De acordo com as estimativas da OMS, mais de 466 milhões de pessoas sofrem de perda auditiva debilitante, sendo as infeções do ouvido a causa mais comum. Os adultos (242 milhões de homens e 190 milhões de mulheres) representam mais de 432 milhões (93 por cento da população), enquanto as crianças representam 34 milhões (7 por cento). A perda auditiva incapacitante afeta cerca de um terço da população com mais de 65 anos. Espera-se que estes desenvolvimentos aumentem a procura de otoscópios, que são normalmente utilizados para diagnosticar problemas de ouvido. De acordo com os Centros de Controlo e Prevenção de Doenças (CDC) dos Estados Unidos, aproximadamente 15% dos americanos (mais de 50 milhões de pessoas) sofrem de zumbidos. Isto aumentará a procura de medicamentos óticos no mercado.

A Data Bridge Market Research analisa que o mercado de drogas óticas foi avaliado em 1,47 mil milhões de dólares em 2021 e deverá atingir os 2,42 mil milhões de dólares até 2029, registando um CAGR de 6,45% durante o período de previsão de 2022 a 2029. Além dos insights de mercado, como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de pesquisa de mercado da Data Bridge também inclui análise aprofundada especializada, epidemiologia do doente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito do relatório e segmentação de mercado

Definição de mercado

Os medicamentos óticos são medicamentos utilizados para tratar infeções de ouvido. A otite média é uma inflamação do ouvido médio que causa disfunção da trompa de Eustáquio após uma infeção viral do trato respiratório superior. A trompa de Eustáquio é uma trompa que liga o ouvido médio à garganta e ao ouvido. Provoca uma acumulação de líquido atrás do tímpano, impedindo a drenagem de líquido do ouvido médio. Quando o líquido do ouvido não drena, desenvolve-se uma infeção no ouvido, resultando numa otite média aguda.

Dinâmica do mercado de medicamentos óticos

Motoristas

• Aumento da taxa de prevalência de infeção do ouvido

Estima-se que a crescente prevalência de infeções do ouvido em todo o mundo expanda a taxa de crescimento do mercado. Devido à inflamação e à acumulação de líquido atrás do tímpano, as infeções de ouvido podem por vezes causar perda de audição. De acordo com a Organização Mundial de Saúde (OMS), quase 2,5 mil milhões de pessoas sofrerão perda auditiva até 2050, sendo que pelo menos 700 milhões necessitarão de reabilitação auditiva.

• Aumentar o investimento em infraestruturas de saúde

Outro fator significativo que influencia a taxa de crescimento do mercado de medicamentos óticos é o aumento dos gastos em saúde, o que ajuda a melhorar as suas infraestruturas. Além disso, várias organizações governamentais pretendem melhorar a infra-estrutura de saúde aumentando o financiamento e isto influenciará ainda mais a dinâmica do mercado.

Além disso, o uso crescente de objetos externos, como cotonetes e ganchos de cabelo, que causam infeções nos ouvidos, e o crescente vício do tabagismo irão expandir o mercado das drogas óticas. Além disso, estima-se que a crescente incidência de infeções virais e o aumento do número de iniciativas governamentais para difundir a consciencialização aumentem a taxa de crescimento do mercado.

Oportunidades

• Aumento do número de atividades de investigação e desenvolvimento    

The otic drugs market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the otic drugs market growth. For instance, Sandoz Inc. introduced Ciprofloxacin 0.3 percent + Dexamethasone 0.1 percent otic solution 7.5mL ear drops in the United States in August 2020 to treat bacterial infections in the middle ear outer ear canal. As a result, product releases like these may positively impact market growth over the predicted period. Smith+Nephew will introduce the first commercial procedure of the Tula System, an in-office option for the installation of tympanostomy tubes in patients with ear infections, in May 2020, bolstering the market.

Moreover, an increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the otic drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the otic drugs market. Additionally, side effects of otic drugs strict FDA guidelines for the drug approval of new drug will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This otic drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the otic drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Otic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

• In August 2020, Dr Reddy's Laboratories announced the launch of a generic version of Ciprodex for the treatment of ear infections in the US. This first-to-market generic version exemplifies the firm's commitment to bringing affordable generic medicines to market for patients.

Global Otic Drugs Market Scope

The otic drugs market is segmented on the basis of type, indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Otitis Media
• Otitis Media with Effusion
• Chronic Otitis Media with Effusion

Indication

• Otitis
• Middle Ear Infections
• Others

Drug Class

• Cerumenolytics
• Otic Anesthetics
• Otic Anti-Infectives
• Otic Steroids
• Others

Route of Administration

• Oral
• Topical
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Otic Drugs Market Regional Analysis/Insights

The otic drugs market is analysed and market size insights and trends are provided by country, type, type, indication, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the otic drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the otic drugs market because of the presence of key manufacturers of the novel technology and rising healthcare expenditure in this region. Additionally, high research and development expenditure and the presence of skilled professionals will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to the increasing prevalence of ear infections and rising healthcare expenditure. Also, the growing number of generic drugs will further cushion the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Otic Drugs Market Share Analysis

The otic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to otic drugs market.

Some of the major players operating in the otic drugs market are:

• Eli Lilly and Company (U.S.)
• AstraZeneca (U.K.)
• Novartis AG (Switzerland)
• Johnson & Johnson Private Limited (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• Bausch Health Companies Inc. (Canada)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Sanofi (France)
• Merck KGaA (Germany)
• Dr. Reddy's Laboratories Ltd. (India)
• Zydus Cadila (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)

SKU-53465